关键词：人类胰岛素；大肠杆菌；基因插入；免疫原性
摘 要：Human insulin is made from human protein, along with minor variations, which is produced by inserting the gene for human insulin into yeast (E. Coli). The minor variations allow these microorganisms to produce the insulin for purification from a bulk suspension. The human insulin does not cause the immunogenic effects that porcine insulin can bring about because it is recognized as human by the body.The Human Insulin market in China is witnessing new developments and innovations every year.There is a vast opportunity for the market to expand in China as it has the largest diabetic population in the world. The Human Insulin market in China is expected to grow at a faster rate than the Global Human Insulin market. As far as vendors are concerned, Novo Nordisk A/S is considered to be the leading vendor in the market. The Human Insulin market in China is expected to grow at a CAGR of 22.5 percent during the period 2011–2015.
目 录：

01. Executive Summary

02. Introduction

03. Market Coverage

Market Overview

Key Offerings

04. Market Landscape

04.1 Insulin Market in China

04.2 Human Insulin Market in China

Market Size

Market Forecast

Five Forces Analysis

05. Rate of Incidence and Prevalence

Diabetes

06. Vendor Landscape

Vendor Strategies

07. Buying Criteria

08. Market Growth Drivers

09. Drivers and their Impact

10. Market Challenges

11. Impact of Drivers and Challenges

12. Market Trends

13. Key Vendor Analysis

13.1 Novo Nordisk A/S

Business Overview

SWOT Analysis

13.2 Sanofi SA

Business Overview

SWOT Analysis

13.3 Eli Lilly and Co.

Business Overview

SWOT Analysis

13.4 Tonghua Dongbao Pharmaceutical Co. Ltd.

Business Overview

SWOT Analysis

14. Other Reports in this Series